← Dashboard
Stock
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LIMITEDLatest close $339 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
9
27 funds tracked
Ever held
16
Current + past
New this quarter
3
Exited this quarter
1
Marquee-fund ownership over time
Feb 14, 2014Feb 13, 2019Feb 14, 2024May 15, 2026
Now
9
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Duquesne Family Office re-entered | Q1 2014 | 50Q | $40 | $33 | -17% |
| Glenview Capital re-entered | Q3 2015 | 44Q | $64 | $33 | -49% |
| Bridgewater Associates re-entered | Q1 2016 | 42Q | $51 | $33 | -35% |
| Greenlight Capital | Q1 2024 | 9Q | $13 | $33 | +149% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $18 | $33 | +82% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $18 | $33 | +82% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $18 | $33 | +82% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $33 | +82% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $33 | +82% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors | Q3 2024 | Q2 2026 | → $34 | +90% |
| Viking Global Investors 3× in & out | Q4 2024 | Q1 2026 | → $34 | +105% |
| Maverick Capital 4× in & out | Q1 2023 | Q1 2026 | → $34 | +232% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | → $34 | +95% |
| Berkshire Hathaway | Q1 2018 | Q1 2022 | → $8.52 | -56% |
| JANA Partners 2× in & out | Q1 2018 | Q2 2019 | → $11 | -41% |
| Appaloosa | Q1 2017 | Q3 2017 | → $17 | -50% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at TEVA PHARMACEUTICAL INDUSTRIES LTD. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
22
Filings · last 90d
27
Total on file
587
Recent SEC buffer
Most recent
Jun 8, 2026
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-261715Jun 8, 2026
- Form 40001193125-26-261712Jun 8, 2026
- Form 40001193125-26-261706Jun 8, 2026
- Form 40001193125-26-261701Jun 8, 2026
- Form 40001193125-26-261691Jun 8, 2026
- Form 40001193125-26-261688Jun 8, 2026
- Form 40001193125-26-261677Jun 8, 2026
- Form 40001193125-26-261676Jun 8, 2026
- Form 40001193125-26-261672Jun 8, 2026
- Form 40001193125-26-261660Jun 8, 2026
- Form 40001193125-26-257344Jun 4, 2026
- Form 40001193125-26-251459Jun 1, 2026
- Form 40001193125-26-251452Jun 1, 2026
- Form 40001193125-26-251441Jun 1, 2026
- Form 40001193125-26-251434Jun 1, 2026
Showing 15 of 587 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · TEVA PHARMACEUTICAL INDUSTRIES LIMITEDAnnual figures sourced directly from TEVA PHARMACEUTICAL INDUSTRIES LIMITED's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$17.26B
FY2025+4% YoY
Net income
$1.41B
FY2025+186% YoY
EPS (diluted)
$1.21
FY2025+183% YoY
Free cash flow(?)
$1.65B
FY2025+32% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for TEVA PHARMACEUTICAL INDUSTRIES LTD — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 28, 2026
- 10-QQuarterly reportApr 29, 2026
- 8-KFORM 8-KApr 29, 2026
- DEF 14AProxy statementMar 31, 2026
- 10-KAnnual reportFeb 3, 2026
- 8-KFORM 8-KJan 28, 2026
- 8-KFORM 8-KJan 12, 2026
- 8-KMaterial eventDec 11, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KFORM 8-KNov 5, 2025
- 10-QQuarterly reportJul 30, 2025
- 8-KFORM 8-KJul 30, 2025
- 8-KMaterial eventJun 5, 2025
- 8-KMaterial eventMay 28, 2025
- 8-KMaterial eventMay 22, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Millennium Management | Q2 2026 | open | $34 | $34 | -1% |
| Point72 Asset Management | Q2 2026 | open | $34 | $34 | -1% |
| Bridgewater Associates | Q4 2025 | open | $26 | $33 | +28% |
| Viking Global Investors | Q4 2024 | Q1 2026 | $17 | $34 | +105% |
| Duquesne Family Office | Q4 2024 | open | $17 | $34 | +103% |
| Citadel Advisors | Q3 2024 | Q2 2026 | $18 | $34 | +90% |
| Two Sigma Investments | Q3 2024 | open | $18 | $34 | +89% |
| D.E. Shaw | Q3 2024 | open | $18 | $34 | +89% |
| AQR Capital Management | Q3 2024 | open | $18 | $34 | +89% |
| Millennium Management | Q3 2024 | Q1 2026 | $18 | $34 | +91% |
| Point72 Asset Management | Q3 2024 | Q1 2025 | $18 | $16 | -10% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | $17 | $34 | +95% |
| Greenlight Capital | Q1 2024 | open | $13 | $34 | +158% |
| Glenview Capital | Q1 2024 | open | $13 | $34 | +158% |
| Maverick Capital | Q1 2023 | Q1 2026 | $10 | $34 | +232% |
| Bridgewater Associates | Q3 2021 | Q2 2025 | $9.83 | $17 | +72% |
| Maverick Capital | Q4 2020 | Q4 2021 | $9.63 | $9.44 | -2% |
| Maverick Capital | Q4 2019 | Q2 2020 | $9.37 | $11 | +20% |
| Maverick Capital | Q1 2019 | Q3 2019 | $17 | $6.30 | -64% |
| Berkshire Hathaway | Q1 2018 | Q1 2022 | $19 | $8.52 | -56% |
| JANA Partners | Q1 2018 | Q2 2019 | $19 | $11 | -41% |
| Appaloosa | Q1 2017 | Q3 2017 | $34 | $17 | -50% |
| Bridgewater Associates | Q1 2016 | Q1 2019 | $51 | $18 | -65% |
| Viking Global Investors | Q4 2015 | Q1 2017 | $55 | $34 | -39% |
| Glenview Capital | Q3 2015 | Q1 2017 | $64 | $34 | -47% |
| Viking Global Investors | Q2 2015 | Q3 2015 | $56 | $64 | +15% |
| Duquesne Family Office | Q2 2015 | Q3 2015 | $56 | $64 | +15% |
| JANA Partners | Q2 2014 | Q3 2014 | $46 | $48 | +4% |
| Duquesne Family Office | Q1 2014 | Q4 2014 | $40 | $52 | +33% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.